A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting 76 enrolled GI Innovation, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors

Timeline

Start: 2025-04-22
Primary completion: 2027-02
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GI-108	Protein / enzyme biologic	0.1 mg/kg	Intravenous
Subject	GI-108	Protein / enzyme biologic	0.6 mg/kg	Intravenous

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Summary

Timeline

Drugs

Indications